JP2020507606A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507606A5 JP2020507606A5 JP2019543998A JP2019543998A JP2020507606A5 JP 2020507606 A5 JP2020507606 A5 JP 2020507606A5 JP 2019543998 A JP2019543998 A JP 2019543998A JP 2019543998 A JP2019543998 A JP 2019543998A JP 2020507606 A5 JP2020507606 A5 JP 2020507606A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- ethyl
- methyl
- alkyl
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 91
- 125000000217 alkyl group Chemical group 0.000 claims description 90
- 150000003839 salts Chemical class 0.000 claims description 77
- -1 N, N-dimethylaminoethyl Chemical group 0.000 claims description 59
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 20
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 15
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 102000001708 Protein Isoforms Human genes 0.000 claims description 14
- 108010029485 Protein Isoforms Proteins 0.000 claims description 14
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000009286 beneficial effect Effects 0.000 claims description 7
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 108090000312 Calcium Channels Proteins 0.000 claims description 6
- 102000003922 Calcium Channels Human genes 0.000 claims description 6
- 102000003691 T-Type Calcium Channels Human genes 0.000 claims description 6
- 108090000030 T-Type Calcium Channels Proteins 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 3
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- IWJOAMCMDKUPSS-NMMIHGMASA-N 3-[(1S,2S)-2-[2-[3-[4,6-bis(trifluoromethyl)-1H-benzimidazol-2-yl]propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl]morpholine-4-carboxylic acid Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=C(C=C4N3)C(F)(F)F)C(F)(F)F)C5COCCN5C(=O)O)C=C(C=C2)F IWJOAMCMDKUPSS-NMMIHGMASA-N 0.000 claims description 2
- IWJOAMCMDKUPSS-UHFFFAOYSA-N 3-[2-[2-[3-[4,6-bis(trifluoromethyl)-1H-benzimidazol-2-yl]propyl-methylamino]ethyl]-6-fluoro-1-propan-2-yl-3,4-dihydro-1H-naphthalen-2-yl]morpholine-4-carboxylic acid Chemical compound CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=C(C=C(C=C4N3)C(F)(F)F)C(F)(F)F)C5COCCN5C(=O)O)C=C(C=C2)F IWJOAMCMDKUPSS-UHFFFAOYSA-N 0.000 claims description 2
- HLKUAFQXZIWWAX-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F HLKUAFQXZIWWAX-UHFFFAOYSA-N 0.000 claims description 2
- VFGMKSLSMTYVIH-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCC(C)(C)C1=NC(C=CC=C2)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F VFGMKSLSMTYVIH-UHFFFAOYSA-N 0.000 claims description 2
- YVSVPYDBLWZNOA-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCC1(CC1)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCC1(CC1)C1=NC(C=CC=C2)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F YVSVPYDBLWZNOA-UHFFFAOYSA-N 0.000 claims description 2
- HHNVXQFSIYTYLZ-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCCC1=NC(C(C)=CC=C2C)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCCC1=NC(C(C)=CC=C2C)=C2N1)(CCC1=C2)C(COCC3)N3C(O)=O)C1=CC=C2F HHNVXQFSIYTYLZ-UHFFFAOYSA-N 0.000 claims description 2
- GFAVBVNVVBMGRL-UHFFFAOYSA-N CC(C)C(C(CCN(C)CCCC1=NC(C(OC)=CC=C2OC)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F Chemical compound CC(C)C(C(CCN(C)CCCC1=NC(C(OC)=CC=C2OC)=C2N1)(CNC(O)=O)CCC1=C2)C1=CC=C2F GFAVBVNVVBMGRL-UHFFFAOYSA-N 0.000 claims description 2
- ARFGYDRJRJNMQI-UHFFFAOYSA-N CC(C)C1C2=C(C=C(C=C2)F)OCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O Chemical compound CC(C)C1C2=C(C=C(C=C2)F)OCC1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O ARFGYDRJRJNMQI-UHFFFAOYSA-N 0.000 claims description 2
- DXZSWYQYGILTFX-UHFFFAOYSA-N CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F Chemical compound CC(C)C1C2=C(CCC1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F DXZSWYQYGILTFX-UHFFFAOYSA-N 0.000 claims description 2
- HLKUAFQXZIWWAX-LMALLOCISA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)C5COCCN5C(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)C5COCCN5C(=O)O)C=C(C=C2)F HLKUAFQXZIWWAX-LMALLOCISA-N 0.000 claims description 2
- VFGMKSLSMTYVIH-FREGXXQWSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC(C)(C)C3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F VFGMKSLSMTYVIH-FREGXXQWSA-N 0.000 claims description 2
- YVSVPYDBLWZNOA-LMALLOCISA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC3(CC3)C4=NC5=CC=CC=C5N4)C6COCCN6C(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCC3(CC3)C4=NC5=CC=CC=C5N4)C6COCCN6C(=O)O)C=C(C=C2)F YVSVPYDBLWZNOA-LMALLOCISA-N 0.000 claims description 2
- DXZSWYQYGILTFX-FREGXXQWSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)Cl)CN(C)C(=O)O)C=C(C=C2)F DXZSWYQYGILTFX-FREGXXQWSA-N 0.000 claims description 2
- GFAVBVNVVBMGRL-FREGXXQWSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)OC)CNC(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=C(C=CC(=C4N3)OC)OC)CNC(=O)O)C=C(C=C2)F GFAVBVNVVBMGRL-FREGXXQWSA-N 0.000 claims description 2
- OPNJAZPBIWUKOY-XTEPFMGCSA-N CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F Chemical compound CC(C)[C@H]1C2=C(CC[C@@]1(CCN(C)CCCC3=NC4=CC=CC=C4N3)CNC(=O)O)C=C(C=C2)F OPNJAZPBIWUKOY-XTEPFMGCSA-N 0.000 claims description 2
- HFCJAYMEPWMHCS-UHFFFAOYSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CCC3(CCC4=C(C3C(C)C)C=CC(=C4)F)CN(C)C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CCC3(CCC4=C(C3C(C)C)C=CC(=C4)F)CN(C)C(=O)O HFCJAYMEPWMHCS-UHFFFAOYSA-N 0.000 claims description 2
- HHNVXQFSIYTYLZ-CMNOXULISA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@@]3(CCC4=C([C@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@@]3(CCC4=C([C@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O HHNVXQFSIYTYLZ-CMNOXULISA-N 0.000 claims description 2
- HHNVXQFSIYTYLZ-ZOAJNJICSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)C5COCCN5C(=O)O HHNVXQFSIYTYLZ-ZOAJNJICSA-N 0.000 claims description 2
- HFCJAYMEPWMHCS-JTSJOTPCSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CN(C)C(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CN(C)C(=O)O HFCJAYMEPWMHCS-JTSJOTPCSA-N 0.000 claims description 2
- RFZTVUJIENHCBI-FREGXXQWSA-N CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CNC(=O)O Chemical compound CC1=C2C(=C(C=C1)C)N=C(N2)CCCN(C)CC[C@]3(CCC4=C([C@@H]3C(C)C)C=CC(=C4)F)CNC(=O)O RFZTVUJIENHCBI-FREGXXQWSA-N 0.000 claims description 2
- PJDNSIZKNZNKCJ-UVOPUAODSA-N CCN(CCCC(=O)NC1=C(C=CC(=C1N)C)C)CC[C@]2(CCC3=C([C@@H]2C(C)C)C=CC(=C3)F)C4COCCN4C(=O)O Chemical compound CCN(CCCC(=O)NC1=C(C=CC(=C1N)C)C)CC[C@]2(CCC3=C([C@@H]2C(C)C)C=CC(=C3)F)C4COCCN4C(=O)O PJDNSIZKNZNKCJ-UVOPUAODSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000016285 Movement disease Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 0 CC(CC=C1C)c2c1nc(*)[n]2C Chemical compound CC(CC=C1C)c2c1nc(*)[n]2C 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GSWJJXXRQOXFCP-UHFFFAOYSA-N CC(C)c1nc(C=CCC2)c2[n]1C Chemical compound CC(C)c1nc(C=CCC2)c2[n]1C GSWJJXXRQOXFCP-UHFFFAOYSA-N 0.000 description 1
- GWZLMUNEDVTESN-UHFFFAOYSA-N Cc1nc(c(OC)ccc2OC)c2[nH]1 Chemical compound Cc1nc(c(OC)ccc2OC)c2[nH]1 GWZLMUNEDVTESN-UHFFFAOYSA-N 0.000 description 1
- NKHMPCKGOLWJGH-MSLMYCKWSA-N Cc1ncc(/C(/Cl)=C\C=C\OC)[nH]1 Chemical compound Cc1ncc(/C(/Cl)=C\C=C\OC)[nH]1 NKHMPCKGOLWJGH-MSLMYCKWSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459355P | 2017-02-15 | 2017-02-15 | |
| US62/459,355 | 2017-02-15 | ||
| PCT/US2018/018356 WO2018152317A1 (en) | 2017-02-15 | 2018-02-15 | Calcium channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507606A JP2020507606A (ja) | 2020-03-12 |
| JP2020507606A5 true JP2020507606A5 (enExample) | 2021-03-25 |
| JP7134178B2 JP7134178B2 (ja) | 2022-09-09 |
Family
ID=63170001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543998A Active JP7134178B2 (ja) | 2017-02-15 | 2018-02-15 | カルシウムチャネル阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11130750B2 (enExample) |
| EP (1) | EP3585376A4 (enExample) |
| JP (1) | JP7134178B2 (enExample) |
| KR (1) | KR102642063B1 (enExample) |
| CN (1) | CN110545806A (enExample) |
| AU (1) | AU2018221722B2 (enExample) |
| CA (1) | CA3053781A1 (enExample) |
| WO (1) | WO2018152317A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| CN119868330A (zh) | 2019-03-01 | 2025-04-25 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ213651A (en) * | 1984-10-11 | 1989-07-27 | Hoffmann La Roche | Tetrahydronapthalene derivatives and medicaments |
| DK171349B1 (da) * | 1986-11-14 | 1996-09-16 | Hoffmann La Roche | Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler |
| WO1993004047A1 (en) | 1991-08-16 | 1993-03-04 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| CA2749312A1 (en) | 1996-02-14 | 1997-08-21 | Novartis Ag | Sugar-modified gapped oligonucleotides |
| AU2001235363A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| NZ533126A (en) | 2002-01-17 | 2006-04-28 | Univ British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| AU2003277418A1 (en) | 2002-10-17 | 2004-05-04 | Merck And Co., Inc. | Enhancement of sleep with t-type calcium channel antagonists |
| US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
| US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
| KR100610731B1 (ko) | 2004-02-24 | 2006-08-09 | 한국과학기술연구원 | Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법 |
| US7504431B2 (en) | 2004-04-16 | 2009-03-17 | Bristol-Myers Squibb Company | Sulfonyl amide inhibitors of calcium channel function |
| CA2576186A1 (en) | 2004-08-20 | 2006-03-02 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| CA2576191C (en) | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| US7745452B2 (en) | 2005-03-09 | 2010-06-29 | Merck Sharp & Dohme Corp. | Quinazolinone T-type calcium channel antagonists |
| CA2611153A1 (en) | 2005-06-23 | 2007-01-04 | Merck & Co., Inc. | 3-fluoro-piperidine t-type calcium channel antagonists |
| CN101212974A (zh) | 2005-06-29 | 2008-07-02 | 默克公司 | 4-氟-哌啶t-型钙通道拮抗剂 |
| KR20080025057A (ko) | 2005-07-14 | 2008-03-19 | 테이진 카세이 가부시키가이샤 | 발포 수지 시트 및 액정 표시 장치 |
| KR100654328B1 (ko) | 2005-08-26 | 2006-12-08 | 한국과학기술연구원 | 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법 |
| EP1968956A2 (en) | 2005-12-22 | 2008-09-17 | Icagen, Inc. | Calcium channel antagonists |
| EP2010493B1 (en) | 2006-04-12 | 2016-01-27 | Merck Sharp & Dohme Corp. | Pyridyl amide t-type calcium channel antagonists |
| KR100743255B1 (ko) | 2006-05-04 | 2007-07-27 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체 |
| KR100749843B1 (ko) | 2006-07-13 | 2007-08-21 | 한국과학기술연구원 | Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법 |
| KR100969686B1 (ko) | 2006-08-07 | 2010-07-14 | 한국과학기술연구원 | 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제 |
| CN101534818A (zh) | 2006-09-15 | 2009-09-16 | 先灵公司 | 用于治疗疼痛和脂类代谢疾病的氮杂环丁烷和氮杂环丁酮衍生物 |
| AR062790A1 (es) | 2006-09-15 | 2008-12-03 | Schering Corp | Derivados de azetidina utiles en el tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos |
| CA2663503A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidinone derivatives and methods of use thereof |
| US7884080B2 (en) | 2006-09-15 | 2011-02-08 | Schering Plough Corporation | Azetidinone derivatives and methods of use thereof |
| CA2663501A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Treating pain, diabetes, and disorders of lipid metabolism |
| WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| CN101686952A (zh) | 2007-03-12 | 2010-03-31 | Vm生物医药公司 | 新型钙离子通道调节剂 |
| WO2008117148A1 (en) | 2007-03-23 | 2008-10-02 | Pfizer Products Inc. | Substituted oxadiazole analogs as calcium channel antagonists |
| WO2008138126A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| KR100863239B1 (ko) | 2007-05-23 | 2008-10-15 | 한국과학기술연구원 | 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제 |
| AU2008275674A1 (en) | 2007-07-10 | 2009-01-15 | Merck & Co., Inc. | Quinazolinone T-type calcium channel antagonists |
| KR101079459B1 (ko) | 2007-09-14 | 2011-11-03 | 이화여자대학교 산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물 |
| MX2010004530A (es) | 2007-10-24 | 2010-05-14 | Merck Sharp & Dohme | Antagonistas de los canales de calcio tipo t de heterociclo fenil amida. |
| EP2211864A1 (en) | 2007-10-24 | 2010-08-04 | Merck Sharp & Dohme Corp. | Pyrazinyl amide t-type calcium channel antagonists |
| CA2702126A1 (en) | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Heterocycle amide t-type calcium channel antagonists |
| WO2009056934A1 (en) | 2007-10-31 | 2009-05-07 | Pfizer Products Inc. | 1,4-dihydronaphthyridine derivatives |
| KR100917037B1 (ko) | 2007-11-01 | 2009-09-10 | 한국과학기술연구원 | 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법 |
| WO2009132454A1 (en) | 2008-04-28 | 2009-11-05 | Neuromed Pharmaceuticals Ltd. | Di-t-butylphenyl piperazines as calcium channel blockers |
| US20090298834A1 (en) | 2008-06-02 | 2009-12-03 | Hassan Pajouhesh | 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers |
| US8377968B2 (en) | 2008-06-02 | 2013-02-19 | Zalicus Pharmaceuticals, Ltd. | N-piperidinyl acetamide derivatives as calcium channel blockers |
| KR101014887B1 (ko) | 2008-06-26 | 2011-02-15 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법 |
| KR20100005476A (ko) | 2008-07-07 | 2010-01-15 | 한국과학기술연구원 | Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법 |
| KR101052620B1 (ko) | 2008-08-28 | 2011-07-29 | 한국과학기술연구원 | 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
| KR101052065B1 (ko) | 2008-10-15 | 2011-07-27 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법 |
| TW201028421A (en) | 2009-01-15 | 2010-08-01 | Abbott Lab | Novel benzenesulfonamides as calcium channel blockers |
| CA2764499A1 (en) | 2009-06-05 | 2010-12-09 | Lloyd S. Gray | Interlaced method for treating cancer or a precancerous condition |
| WO2011109262A2 (en) | 2010-03-01 | 2011-09-09 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| US8575361B2 (en) | 2010-03-02 | 2013-11-05 | Concert Pharmaceuticals Inc. | Tetrahydronaphthalene derivatives |
| WO2012094615A2 (en) | 2011-01-07 | 2012-07-12 | Zenyaku Kogyo Kabushikikaisha | Use of cav3.1 selective t-type calcium channel antagonists |
| US9839622B2 (en) | 2012-05-08 | 2017-12-12 | Zafgen, Inc. | Methods of treating hypothalamic obesity |
| KR20150108853A (ko) | 2013-01-10 | 2015-09-30 | 타우 쎄라퓨틱스 엘엘씨 | 암의 치료를 위한 t-타입 칼슘 채널 억제제 |
| KR101679262B1 (ko) * | 2015-06-08 | 2016-11-24 | 한국과학기술연구원 | 4-이소프로필크로만-3-올 화합물 |
| AU2016341429B2 (en) | 2015-10-22 | 2023-09-21 | Cavion, Inc. | Methods for treating Angelman Syndrome and related disorders |
| KR102654466B1 (ko) | 2017-04-26 | 2024-04-08 | 카비온, 인코포레이티드 | 기억 및 인지 개선 방법 및 기억 및 인지 장애 치료 방법 |
| SG11201909963YA (en) | 2017-04-26 | 2019-11-28 | Cavion Inc | Methods for treating dravet syndrome |
-
2018
- 2018-02-15 US US16/486,399 patent/US11130750B2/en active Active
- 2018-02-15 CN CN201880024040.6A patent/CN110545806A/zh active Pending
- 2018-02-15 WO PCT/US2018/018356 patent/WO2018152317A1/en not_active Ceased
- 2018-02-15 AU AU2018221722A patent/AU2018221722B2/en active Active
- 2018-02-15 KR KR1020197027037A patent/KR102642063B1/ko active Active
- 2018-02-15 CA CA3053781A patent/CA3053781A1/en active Pending
- 2018-02-15 JP JP2019543998A patent/JP7134178B2/ja active Active
- 2018-02-15 EP EP18755079.3A patent/EP3585376A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507606A5 (enExample) | ||
| JP2016053042A5 (enExample) | ||
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| JP2012508252A5 (enExample) | ||
| JP2014503567A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| JP2014051526A5 (enExample) | ||
| JP2016513737A5 (enExample) | ||
| JP2021504317A5 (enExample) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2009504764A5 (enExample) | ||
| JP2017528524A5 (enExample) | ||
| RU2018129308A (ru) | Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| JP2020527173A5 (enExample) | ||
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| CN111601797A (zh) | 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用 | |
| JP2014520108A5 (enExample) | ||
| JP2005506982A5 (enExample) | ||
| RU2015113597A (ru) | Производные аминоизохинолина в качестве ингибиторов протеинкиназы | |
| JP2012519703A5 (enExample) |